0
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.
CEO Gustav H. Gram gave an online interview and Q&A at 14:00 CET on 10 February 2026, in connection with the publication of the company's H2 / Year-end report. The event was streamed together with Infront Direkt Studios.
The H2 / Year-end report can be found here. https://pilapharma.com/Image/Reports/YEAR-END_REPORT_2025_PILA_PHARMA_AB_1-JANUARY_31-December_2025.pdf
During the session, CEO Gustav H. Gram discussed key highlights from the report and provided comments on:
The current cash position and cash runway
PILA PHARMA's recent preclinical studies
The ongoing TO2 warrant period
The future plans with progress to the clinical part of the Company's 'bet on obesity'
The announced clinical preparations in the rare disease erythromelalgia
OBS: Pila Pharma har en betalt digital IR-aftale med ProInvestor.com
CEO Gustav H. Gram gave an online interview and Q&A at 14:00 CET on 10 February 2026, in connection with the publication of the company's H2 / Year-end report. The event was streamed together with Infront Direkt Studios.
The H2 / Year-end report can be found here. https://pilapharma.com/Image/Reports/YEAR-END_REPORT_2025_PILA_PHARMA_AB_1-JANUARY_31-December_2025.pdf
During the session, CEO Gustav H. Gram discussed key highlights from the report and provided comments on:
The current cash position and cash runway
PILA PHARMA's recent preclinical studies
The ongoing TO2 warrant period
The future plans with progress to the clinical part of the Company's 'bet on obesity'
The announced clinical preparations in the rare disease erythromelalgia
OBS: Pila Pharma har en betalt digital IR-aftale med ProInvestor.com
